NGP-555 / NeuroGenetic Pharma - LARVOL DELTA

NGP 555, a γ-secretase modulator, shows a beneficial shift in the ratio of amyloid biomarkers in human cerebrospinal fluid at safe doses. (PubMed, Alzheimers Dement (N Y)) - "In humans, NGP 555 has demonstrated a beneficial shift in the production of Aβ and Aβ versus Aβ biomarker levels in the cerebrospinal fluid while maintaining an adequate safety profile. The overall clinical goal is to achieve an optimal balance of efficacy for altering amyloid-β peptide (Aβ) biomarkers while maintaining a safe profile so that NGP 555 can be given early in AD to prevent production of Aβ and accumulation of amyloid plaques, in an effort to prevent aggregation of tau and destruction of neurons and synapses resulting in cognitive decline."

Biomarker • Journal